Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 3/20 | 0.66 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.66 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598538 | 0.81 | SMARCA2 (0.43) | SMARCA2PBRM1SMARCA4ADORA1ADORA2A | |
| SCHEMBL10634913 | 0.79 | SMARCA2 (1.00) | SMARCA2PBRM1SMARCA4BRD4NR1I2 | |
| SCHEMBL29912639 | 0.79 | SMARCA2 (1.00) | SMARCA2PBRM1SMARCA4BRD4NR1I2 | |
| SCHEMBL2335714 | 0.76 | CASP1 (0.53) | SMARCA2PBRM1SMARCA4GSK3AGSK3B | |
| SCHEMBL1752783 | 0.76 | SMARCA2 (0.66) | SMARCA2PBRM1SMARCA4BRD4NR1I2 | |
| SCHEMBL31396251 | 0.74 | PBRM1 (0.66) | SMARCA2PBRM1SMARCA4BRD4NR1I2 | |
| SCHEMBL14890414 | 0.72 | GABRG2 (0.54) | GABRG2GABRB3GABRA5GABRA3NPC1 | |
| SCHEMBL14944040 | 0.72 | SMARCA2 (0.82) | SMARCA2PBRM1SMARCA4BRD4NR1I2 | |
| SCHEMBL14387450 | 0.72 | SMARCA2 (0.59) | SMARCA2PBRM1SMARCA4BRD4NR1I2 | |
| SCHEMBL3646802 | 0.72 | SMARCA2 (0.59) | SMARCA2PBRM1SMARCA4BRD4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104024261-B | Imidazopyridazine compounds | HOFFMAN-LA ROCHE LTD. (CH) | 2016-11-30 | — | — | CN | disclosed |
| US-9169259-B2 | Imidazopyridazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169259-B2 | Imidazopyridazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169259-B2 | Imidazopyridazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2773645-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| WO-2013064445-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064445-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| EP-2324021-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015803-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R & D MANAGEMENT CO. LTD (JP) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015803-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R & D MANAGEMENT CO. LTD (JP) | 2010-02-11 | — | — | WO | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | SMARCA2 2813/4885PBRM1 1365/4885SMARCA4 1952/4885 |
| US-20110195951-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | DAPK1, DAPK2, DAPK3 | SMARCA2 4389/4885PBRM1 3742/4885SMARCA4 4672/4885 |
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | SYK, BTK, IRAK4 | SMARCA2 3440/4885PBRM1 1041/4885SMARCA4 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.